Share on StockTwits

Recro Pharma (NASDAQ:REPH) CAO Donna Nichols acquired 1,200 shares of the stock in a transaction that occurred on Thursday, May 15th. The stock was purchased at an average price of $6.66 per share, with a total value of $7,992.00. Following the completion of the acquisition, the chief accounting officer now directly owns 1,200 shares in the company, valued at approximately $7,992. The acquisition was disclosed in a document filed with the SEC, which is available at this link.

Separately, analysts at Brean Capital initiated coverage on shares of Recro Pharma in a research note on Wednesday, March 19th. They set a “buy” rating and a $26.00 price target on the stock.

Shares of Recro Pharma (NASDAQ:REPH) traded up 3.02% on Thursday, hitting $6.49. The stock had a trading volume of 27,610 shares. Recro Pharma has a 52-week low of $5.01 and a 52-week high of $9.88. The stock’s 50-day moving average is $6.49 and its 200-day moving average is $6.99. The company’s market cap is $11.4 million.

Recro Pharma (NASDAQ:REPH) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.16. On average, analysts predict that Recro Pharma will post $-1.66 earnings per share for the current fiscal year.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.